Candel Therapeutics, Inc. CADL Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s interest expense?
- Candel Therapeutics, Inc. (CADL) reported interest expense of $1.56M in Q1 2026.
- How has Candel Therapeutics, Inc.'s interest expense changed year-over-year?
- Candel Therapeutics, Inc.'s interest expense increased by 411.1% year-over-year, from $306K to $1.56M.
- What is the long-term trend for Candel Therapeutics, Inc.'s interest expense?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s interest expense has grown at a 7.5% compound annual growth rate (CAGR), from $1.71M to $2.12M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.